139sek
2,6 %
Date:2025-05-14Time:17:24:44Latest report:Q1-2025List:First NorthTicker:MODTX
Market Cap:50 msekEnterprise Value:44 msekNet Sales:- msekEarnings:-15,3 msekEmployees:0ISIN:SE0015987904

Ratios

10-year key figure history for Modus Therapeutics turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Modus Therapeutics with index and moving average MA50 and MA200.

Stockprice:1,39
MA50:1,29
MA200:1,46
Price/MA200:-5,0 %
RSI (14):55,6
Price/MA50:7,7 %

Description

Modus Therapeutics operates in the biotechnology industry. The product portfolio is broad and includes, for example, sevuparin. The company's focus is to develop sevuparin for patients with sepsis / septic shock, a serious and often fatal condition. In addition to the main business, service and associated ancillary services are also offered. The activities with associated research are conducted in Sweden.

Biotechnology